• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: BRAC Lending Group LLC returned 869,565 units of Common Stock to the company, decreasing direct ownership by 60% to 590,435 units (Amendment)

    6/4/21 9:40:44 AM ET
    $BRPA
    Business Services
    Finance
    Get the next $BRPA alert in real time by email
    SEC FORM 4/A SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    BRAC Lending Group LLC

    (Last) (First) (Middle)
    366 MADISON AVENUE, 8TH FLOOR

    (Street)
    NEW YORK NY 10017

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    NRX Pharmaceuticals, Inc. [ BRPA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/24/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    05/25/2021
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/24/2021 D 869,565 D $0 590,435(1) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Form 4 filed on May 25, 2021, erroneously reported 562,435 shares beneficially owned in Column 5. This amendment is being filed to correct the total shares beneficially owned in Column 5.
    /s/ David M. Nussbaum. Managing Member 06/04/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BRPA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BRPA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BRPA
    SEC Filings

    View All

    SEC Form 8-K filed by Big Rock Partners Acquisition Corp.

    8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

    5/28/21 5:26:36 PM ET
    $BRPA
    Business Services
    Finance

    Big Rock Partners Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Unregistered Sales of Equity Securities, Changes in Registrant’s Certifying Accountant, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Change in Shell Company Status

    8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

    5/28/21 5:26:03 PM ET
    $BRPA
    Business Services
    Finance

    SEC Form 8-K filed by Big Rock Partners Acquisition Corp.

    8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

    5/26/21 4:13:58 PM ET
    $BRPA
    Business Services
    Finance

    $BRPA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: BRAC Lending Group LLC returned 869,565 units of Common Stock to the company, decreasing direct ownership by 60% to 590,435 units (Amendment)

    4/A - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    6/4/21 9:40:44 AM ET
    $BRPA
    Business Services
    Finance

    SEC Form 4 filed by Big Rock Partners Acquisition Corp.

    4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    5/25/21 9:17:34 PM ET
    $BRPA
    Business Services
    Finance

    SEC Form 4 filed by Big Rock Partners Acquisition Corp.

    4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    5/25/21 8:02:21 PM ET
    $BRPA
    Business Services
    Finance

    $BRPA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update

    RADNOR, Pa., Aug. 16, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (NASDAQ:NRXP), a clinical stage biopharmaceutical company today provided a business update and financial results for the quarter ended June 30, 2021. NRx will host a conference call Tuesday, August 17, 2021, at 8:30AM Eastern Time to discuss its business update and second quarter financial results. "NRx is pleased to report its first quarterly results as a publicly-traded company. We have continued to make substantial progress as a company with the filing of an EUA request for ZYESAMI in the US on May 31st, and the filing and granting of an EUA in the Nation of Georgia, with first orders expected shortly. We are honored to

    8/16/21 9:32:00 PM ET
    $BRPA
    $NRXP
    Business Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq:BRPA)

    RADNOR, Pa., May 25, 2021 /PRNewswire/ -- Today, NeuroRx, Inc., announced it has been approved by the Nasdaq for listing on the Nasdaq Global Market, following the completion of its business combination with Big Rock Partners Acquisition Corp. (NASDAQ:BRPA). The combined entity is NRx Pharmaceuticals, Inc. and will trade on the Nasdaq Global Market as NRXP. NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP"Today marks a major milestone as we include public investors in our quest to bring innovative medicines to patients at immediate risk of death, who have no curr

    5/25/21 6:48:00 AM ET
    $BRPA
    Business Services
    Finance

    Big Rock Partners Acquisition Corp. Announces Effectiveness of Registration Statement; Confirms Annual Meeting Date of May 24, 2021 to Approve Proposed Merger with NeuroRx

    Big Rock Partners Recommends All Stockholders Vote "FOR" ALL Proposals at Annual Meeting NEW YORK, NY / ACCESSWIRE / May 21, 2021 / Big Rock Partners Acquisition Corp. ("Big Rock" or "BRPA") (NASDAQ:BRPA), a publicly traded special purpose acquisition company, today confirmed that its Annual Meeting of Stockholders (the "Annual Meeting") to consider the previously announced merger agreement with NeuroRx, Inc. ("NeuroRx" or the "Company") will take place on May 24, 2021. Stockholders of record as of April 23, 2021 (the "Record Date") are eligible to vote at the Annual Meeting.Big Rock also announced that the U.S. Securities and Exchange Commission has declared effective its registration state

    5/21/21 6:40:00 PM ET
    $BRPA
    Business Services
    Finance

    $BRPA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Big Rock Partners Acquisition Corp. (Amendment)

    SC 13D/A - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

    6/4/21 10:17:16 AM ET
    $BRPA
    Business Services
    Finance

    SEC Form SC 13D filed by Big Rock Partners Acquisition Corp.

    SC 13D - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

    6/3/21 5:30:14 PM ET
    $BRPA
    Business Services
    Finance

    SEC Form SC 13D/A filed by Big Rock Partners Acquisition Corp. (Amendment)

    SC 13D/A - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

    5/26/21 5:02:30 PM ET
    $BRPA
    Business Services
    Finance

    $BRPA
    Financials

    Live finance-specific insights

    View All

    NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update

    RADNOR, Pa., Aug. 16, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (NASDAQ:NRXP), a clinical stage biopharmaceutical company today provided a business update and financial results for the quarter ended June 30, 2021. NRx will host a conference call Tuesday, August 17, 2021, at 8:30AM Eastern Time to discuss its business update and second quarter financial results. "NRx is pleased to report its first quarterly results as a publicly-traded company. We have continued to make substantial progress as a company with the filing of an EUA request for ZYESAMI in the US on May 31st, and the filing and granting of an EUA in the Nation of Georgia, with first orders expected shortly. We are honored to

    8/16/21 9:32:00 PM ET
    $BRPA
    $NRXP
    Business Services
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care